Clinical Trial Detail

NCT ID NCT03449381
Title This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

glioblastoma multiforme

sarcoma

lung non-squamous non-small cell carcinoma

Advanced Solid Tumor

transitional cell carcinoma

Therapies

BI 907828

Age Groups: adult senior

No variant requirements are available.